Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

The overall uptake of RSV vaccine is low during its first season in those aged 60 years or older in the United States. The ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized ...

Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

Nearly 72% of infants were found to be immunized against respiratory syncytial virus, according to study findings.

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional ...